{"Clinical Trial ID": "NCT01237327", "Intervention": ["INTERVENTION 1:", "- Exemestane", "Exemestane 25 milligrams (mg) oral tablet once daily", "INTERVENTION 2:", "- Megestrol acetate", "One 160 mg tablet of megestrol acetate is taken once daily."], "Eligibility": ["Incorporation criteria:", "Previous participation in study 971-ONC-0028-080.", "- Exclusion criteria:", "Topics that had not previously participated in study 971-ONC-0028-080."], "Results": ["Performance measures:", "Overall survival", "Overall survival in months, measured from the start date of treatment in the baseline study to the date of death, regardless of the reason.", "Time limit: Every 12 weeks up to 6 years", "Results 1:", "Title of the arm/group: Exemestane", "Description of the arm/group: Exemestane 25 milligrams (mg) oral tablet taken once daily", "Total number of participants analysed: 43", "Median (95% confidence interval)", "Unit of measure: months 29.2 (22.9 to 47.8)", "Results 2:", "Title of the arm/group: Acetate of Megestrol", "Description of the arm/group: Megestrol acetate 160 mg tablet once daily", "Total number of participants analysed: 41", "Median (95% confidence interval)", "Unit of measure: month 16.3 (11.6 to 27.6)"], "Adverse Events": ["Undesirable Events 1:", "Total: 1/41 (2.44 per cent)", "- Thoracic pain NEC 0/41 (0.00 %)", "Back pain 0/41 (0.00 %)", "Brain haemorrhage 0/41 (0.00 %)", "- Headache NOS 0/41 (0.00 %)", "- Spinal cord pressure 0/41 (0.00 %)", ":: Suicide completed 1/41 (2.44 per cent)", "Adverse Events 2:", "Total: 2/40 (5.0 per cent)", "- Thoracic pain NEC 1/40 (2.50%)", "Back pain 1/40 (2.50%)", "1/40 (2.50%) brain haemorrhage", "- Headache NOS 1/40 (2.50%)", "1/40 Spinal cord compress (2.50%)", "Total suicide rate 0/40 (0.00%)"]}